| Thyroid Disease |
1 |
1 |
| Thyroid Associated Eye Disease |
0 |
0.97 |
| Hyperthyroidism |
0 |
0.81 |
| Thyroid |
0 |
0.75 |
| Orbit |
0 |
0.45 |
| Europe |
0 |
0.15 |
| Biologic Therapy |
0 |
0.12 |
| Patient Safety |
0 |
0.12 |
| Adverse Effects |
0 |
0.1 |
| Clinical Guidelines |
0 |
0.1 |
| Diplopia |
0 |
0.1 |
| Disease Management |
0 |
0.1 |
| Glucocorticoid |
0 |
0.1 |
| Graves Disease |
0 |
0.1 |
| Quality of Life |
0 |
0.1 |
| Referral |
0 |
0.1 |
| Optic Neuropathy |
0 |
0.07 |
| Care and Maintenance of Vision |
0 |
0.06 |
| Healthcare and Medical Technology |
0 |
0.06 |
| Pain Management |
0 |
0.06 |
| Antineoplastic Drug |
0 |
0.05 |
| Biomarker |
0 |
0.05 |
| Clinical Research |
0 |
0.05 |
| Drug Costs |
0 |
0.05 |
| Edema |
0 |
0.05 |
| Exophthalmos |
0 |
0.05 |
| Gland |
0 |
0.05 |
| Intravenous |
0 |
0.05 |
| Kidney |
0 |
0.05 |
| Monoclonal Antibody |
0 |
0.05 |
| Neuropathy |
0 |
0.05 |
| New York |
0 |
0.05 |
| Pain |
0 |
0.05 |
| Receptors |
0 |
0.05 |
| Stress |
0 |
0.05 |